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The questions raised by Behre et al.
1 are important and further data and discussion will make these issues more clear. The study described in our paper 2 was an open-labeled randomized clinical trial on cotransplantation of hematopoietic stem cells with or without culture-expanded mesenchymal stem cells (MSC) from the same donor in human leukocyte antigen (HLA)-identical sibling-matched hematopoietic stem cell transplantation. A total of 30 patients were enrolled and allocated into two groups by using stratified random method according to the enrolled time, age, disease types, stage and prognosis.
Firstly, Behre et al. think the transplantation of bone marrow (BM) as a cotransplantation of MSC. BM is well known as a major source of MSCs, but this population is rare (0.001-0.01%) 3 and unlikely to exert potent immunosuppressive function, which is proven dose-dependent by many studies. 4 Furthermore, MSCs have also been isolated and expanded from mobilized peripheral blood recently.
5 Thus, we do not agree with Behre et al. that the patients who received BM or BM together with peripheral blood stem cells should be regrouped into MSC group, as they received a marrow graft containing MSC. In coincidence, several large randomized studies showed that the incidence of acute graft-versus-host disease was similar in the recipients of peripheral blood and those of bone marrow.
6,7
Secondly, they wondered whether we missed more precise disease characteristics that impact on relapse likelihood. This is a critical question. Acute myeloid leukemia with a complex aberrant karyotype or FLT3 mutations is associated with a dismal outcome. In our study, four patients in each group did not undergo karyotype detection because they had received standard induction therapy in other hospitals and got complete remission when they were referred to our hospital for bone marrow transplantation. None of the remained 22 patients had a complex aberrant karyotype. Unfortunately, the FLT3 mutation analysis was not routinely performed in our hospital before 2005. A detailed profile of the patients is shown in Table 1 . In conclusion, we noted a higher rate of relapse and a lower rate of GVHD in the MSC-treated group than in the control group. Based on the tendency of higher relapse in the MSC group and the evidence showing that MSC promote tumor growth in animal studies, we had to stop this clinical trial prematurely. However, a large cohort of patients is required for multivariate analysis to elucidate whether MSC is a single independent factor affecting the relapse and GVHD rates. Therefore, the use of MSCs in malignant diseases must be handled with extreme caution before a large-scale clinical trial is performed. 
5-Azacitidine has limited therapeutic activity in myelofibrosis
Leukemia ( Patients with primary and post-essential thrombocythemiaFpolycythemia vera myelofibrosis (PMF and post-ET/PV MF)Fhave a progressive decline marked by progressive cytopenias, extramedullary hematopoiesis (manifesting as splenomegaly and/or hepatomegaly), significant constitutional symptoms, potential for blastic transformation and premature death with current therapies rarely offering more than palliative benefit. 1 We have explored many therapeutic targets in these patients including farnesyl-transferase inhibition, 2 proteosome inhibition 3 and immunomodulation with lenalidomide.
4,5
The use of DNA hypomethylation therapy has been found to be efficacious in patients with myelodysplastic syndrome (MDS) leading to the improvement in disease-associated cytopenias, delay in transformation to acute myeloid leukemia and improved survival.
6,7 Additionally, these agents have demonstrated activity in the myeloproliferative disorder (MPD)-MDS overlap syndrome of chronic myelomonocytic leukemia, which shares both the intrinsic proliferative phenotype of PMF and the ineffective hematopoiesis shared by MDS and PMF. 8 There are currently two federal drug administration (FDA)-approved agents in the United States of America including both 5-AZA and Decitabine (Dacogen, MGI Pharma, Bloomington, MN, USA).
Quintas-Cardama et al. 9 recently reported in Leukemia the results of a phase II trial of the DNA hypomethylation agent 5-Azacitidine (5-AZA) (Vidaza; Pharmion Boulder, CO, USA) in patients with PMF and post-ET/PV MF. This latter trial utilized the currently FDA-approved dose and schedules in patients with MDS (75 mg/m 2 subcutaneously for 7 days every 4 weeks). With this latter regimen, the authors reported limited therapeutic benefit with one patient experiencing a partial response (3%) and 21% with a clinical improvement (mainly splenomegaly) by the International Working Group for Myelofibrosis Research and Treatment criteria. Responses were generally of modest duration with a median of 4 months (range: 2-22 months) in duration.
Although 5-AZA has traditionally been administered in a 7-day (total 525 mg/m 2 /cycle) regimen, interest has remained high for a 5 day (total 375 mg/m 2 /cycle) alternative regimen to facilitate ease of administration (no weekend dosing) and hopefully less toxicity. 10 Recent results in MDS demonstrated comparable efficacy with 5-day 5-AZA in MDS. We designed and initiated a 5-day 5-AZA trial in PMF (post-PV/ET MF) to compliment the results of the trial published by QuintasCardama et al.
9 to address whether the activity observed in that latter trial would be maintained in an abbreviated dosing trial in patients with symptomatic PMF (and post-ET/PV MF).
A total of 10 patients were enrolled in this alternate dose/ schedule trial of 5-AZA in PMF (n ¼ 8) or (post-ET/PV MF (one each)). Demographic features were typical for the disorder (outlined in Table 1 ) and are very similar to those patients enrolled in the 7-day trial published by Quintas-Cardama et al.
9
Therapy with the abbreviated 5-day 5-AZA was clinically ineffective for the patients with myelofibrosis, a decreased benefit as to what had been observed with the 7-day regimen. Utilizing the International Working Group for Myelofibrosis Research and Treatment response criteria, 11 no patient achieved even a clinical improvement (the minimal response recognized)
